Key result
Clopidogrel is linked to fatal liver injury 19 days after initiation in a case report.
Case Report (n=1)
This case report highlights a rare but fatal liver injury associated with clopidogrel therapy following percutaneous coronary stenting.
Rare fatal hepatotoxicity may occur with clopidogrel post-stenting; single case leaves open causality and incidence.
Clopidogrel, an adenosine diphosphate receptor blocker, is widely used as an adjunctive antiplatelet therapy in acute coronary syndrome and percutaneous coronary stenting. It appears to be a safe drug with few occurrences of liver side-effects that usually resolved after drug withdrawal. We report a serious liver injury with fatal outcome in a 63-year-old man developed 19 days after starting clopidogrel for percutaneous coronary stenting.
No takes yet. Share an insight, caveat, or question.
Kastalli et al. (2009) conducted a case report in Percutaneous coronary stenting (n=1). Clopidogrel was evaluated on Serious liver injury with fatal outcome. Clopidogrel use for percutaneous coronary stenting was associated with a serious and fatal liver injury in a 63-year-old man 19 days after initiation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: